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Abstract
Background and Purpose: Tranilast, in addition to its capacity to inhibit mast cell degranulation, has other biological
effects, including inhibition of reactive oxygen species, cytokines, leukotrienes and prostaglandin release. In the current
study, we analyzed whether tranilast could alter endothelial function in rat mesenteric resistance arteries (MRA).
Experimental Approach: Acetylcholine-induced relaxation was analyzed in MRA (untreated and 1-hour tranilast treatment)
from 6 month-old Wistar rats. To assess the possible participation of endothelial nitric oxide or prostanoids, acetylcholine-
induced relaxation was analyzed in the presence of L-NAME or indomethacin. The participation of endothelium-derived
hyperpolarizing factor (EDHF) in acetylcholine-induced response was analyzed by preincubation with TRAM-34 plus apamin
or by precontraction with a high K+ solution. Nitric oxide (NO) and superoxide anion levels were measured, as well as
vasomotor responses to NO donor DEA-NO and to large conductance calcium-activated potassium channel opener NS1619.
Key Results: Acetylcholine-induced relaxation was greater in tranilast-incubated MRA. Acetylcholine-induced vasodilation
was decreased by L-NAME in a similar manner in both experimental groups. Indomethacin did not modify vasodilation.
Preincubation with a high K+ solution or TRAM-34 plus apamin reduced the vasodilation to ACh more markedly in tranilast-
incubated segments. NO and superoxide anion production, and vasodilator responses to DEA-NO or NS1619 remained
unmodified in the presence of tranilast.
Conclusions and Implications: Tranilast increased the endothelium-dependent relaxation to acetylcholine in rat MRA. This
effect is independent of the nitric oxide and cyclooxygenase pathways but involves EDHF, and is mediated by an increased
role of small conductance calcium-activated K+ channels.
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Introduction
Mesenteric blood flow can constitute up to 20–30% of total
cardiac output [1] and is regulated by different mechanisms in
which endothelial factors like nitric oxide (NO), prostanoids and
endothelium-derived hyperpolarizing factor (EDHF) play a pivotal
role. Modifications in the release and/or participation of these
vasoactive substances can alter peripheral vascular resistance, with
the role of resistance vessels being especially relevant.
Mast cells play an important role in several physiological and
pathological situations such as intestinal motility, angiogenesis and
atherosclerosis [2–4]. When activated, mast cells secrete numerous
vasoactive and proinflammatory mediators, such as histamine,
serotonin, bradykinin, endothelin, NO, leukotrienes, prostaglan-
dins, or cytokines [5], which could alter vascular endothelial and
smooth muscle function [6]. These consequences are highly
interesting, particularly aspects of hemodynamic changes when
mast cells are stabilized. Tranilast was initially used to treat allergic
diseases due to its capacity to inhibit mast cell degranulation [7]
and has also been suggested in the treatment of multiple
inflammatory processes, including various pathologies where
blood flow is altered, such as in the vasodilation induced by
allergic processes [8–11].
Previously our group has described that lipopolysaccharide, a
model of endotoxic shock, influences vascular tone by modifying
both endothelial and neuronal factors [12,13]. Additionally, we
have studied the effect of tranilast on the vasoconstrictor response
produced by electrical field stimulation (EFS) in rat superior
mesenteric arteries, demonstrating that it diminished the vaso-
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constrictor response to EFS by decreasing noradrenaline-induced
vasoconstriction [14] although it did not influence endothelial
function in this artery, as similarly reported by Yang et al [15] in
rat aorta. However, mesenteric resistance arteries play a pivotal
role in the regulation of vascular resistance, and differences in
endothelial function have been previously described in different
vascular beds under the same experimental conditions [16,17].
With this in mind, the possible effect of tranilast on endothelial
function in resistance vessels may help induce hemodynamic
changes that could be relevant in the treatment of pathologies like
allergy.
Since total peripheral resistance mainly depends on resistance
vessels, and the role that mesenteric resistance arteries play in this
is very relevant, we consider it very important to analyze the
possible alterations tranilast may produce in the endothelial
function of these vessels.
Materials and Methods
Ethics Statement
All animals were housed in the Animal Facility of the
Universidad Auto´noma de Madrid (Registration number EX-
021U) in accordance with directive 609/86 of the E.E.C., R.D.
233/88 of the Ministerio de Agricultura, Pesca y Alimentacio´n of
Spain, and Guide for the Care and Use of Laboratory Animals
published by the USA National Institutes of Health [NIH
publication No. 85.23, revised 1985]. The experimental protocol
was approved by the Ethics Committee of the Universidad
Auto´noma de Madrid.
Animals
We used 6 month-old male Wistar rats. Rats were sacrificed by
CO2 inhalation followed by decapitation; the mesenteric vascular
bed was removed and placed in cold (4uC) Krebs-Henseleit
solution (KHS; in mmol/L: 115 NaCl, 2.5 CaCl2, 4.6 KCl, 1.2
KH2PO4, 1.2, MgSO4.7H2O, 25 NaHCO3, 11.1 glucose, and
0.03 EDTA).
Perivascular mast cell detection
The third-order branches from mesenteric resistance arteries
were fixed in 4% formaldehyde in phosphate buffered saline
solution (PBS, pH = 7.4) for 1 hour, cryoprotected with 30%w/v
sucrose in PBS (overnight), transferred to a cryomold containing
Tissue-Tek OCT embedding medium (20 min) and then imme-
diately frozen in liquid nitrogen. All samples were kept at 270uC
until the day of the experiments. Frozen tissue segments were cut
into 10 mm thick sections, placed on glass slides and stained with
0.1% Toluidine Blue (3 min) for perivascular mast cell detection,
as previously described [14]. Sections were coverslipped and light
microscopy images were taken (Nikon Eclipse TE2000-S [inverted
microscope], Nikon DXM1200F [digital camera]).
Vascular reactivity study
For reactivity experiments the third-order branch of the
mesenteric arcade was dissected and cut in segments of
approximately 2 mm in length. Segments of mesenteric resistance
arteries were mounted in a small vessel chamber myograph
(Danish Myo Technology A/S, A¨arhus, Denmark) to measure
isometric tension according to the method described by Mulvany
and Halpern [18]. After a 15-min equilibration period in
oxygenated KHS at 37uC and pH 7.4, segments were stretched
to their optimal lumen diameter for active tension development.
Optimal lumen diameter was determined based on the internal
circumference/wall tension ratio of the segments by setting the
internal circumference, L 0, to 90% of what the vessels would have
if they were exposed to a passive tension equivalent to that
produced by a transmural pressure of 100 mmHg [18]. Optimal
lumen diameter was determined using specific software for
normalization of resistance arteries (DMT Normalization Module;
ADInstruments Pty Ltd, Castle Hill, Australia). Segments were
washed with KHS and left to equilibrate for 30 min. Vessel
contractility was then tested by an initial exposure to a high-K+
(120 mmol/L) solution.
After washout, segments were contracted with a concentration
of noradrenaline that induced approximately 50%–70% of the
maximum contraction elicited by KCl, and then acetylcholine
(1 mmol/L) was added to assess the integrity of the endothelium.
Some segments were subjected to mechanical endothelium
removal. The absence of endothelium was confirmed by the
inability of acetylcholine (1 mmol/L) to induce relaxation.
Endothelium removal did not modify KCl- (120 mmol/L) induced
contraction.
Since the level of smooth muscle constriction can itself
antagonize the extent of the endothelium-dependent relaxation,
we performed the following experiments adjusting the dose of NA
or KCl to a concentration which allowed us to reach a 50–70% of
the maximum contraction elicited by KCl.
Experimental protocols
The segments were rinsed with KHS for 1 h and then a
cumulative concentration-response curve to ACh (0.1 nmol/L to
3 mmol/L) was obtained in noradrenaline-precontracted segments
preincubated or not with tranilast (100 mmol/L, 1 hour, time and
dose obtained from previous pilot studies). The concentration of
tranilast used and the time of incubation were from previous pilot
studies, performed similarly to our previous study [14]. Addition-
ally, vasoconstrictor responses to alpha-adrenergic agonist nor-
adrenaline (10 nmol/L to 0.1 mmol/L) were performed in both
control and tranilast-incubated segments.
The possible role of NO in ACh-induced relaxation was
investigated in tranilast-treated and untreated segments by
preincubation with 100 mmol/L L-NAME (a non-selective nitric
oxide synthesis inhibitor) before performing concentration-re-
sponse curves to ACh. Additionally, endothelium-independent
relaxation was studied by evaluating relaxation to NO donor
DEA-NO (10 nmol/L to 300 mmol/L) in arteries previously
contracted with noradrenaline.
The role of EDHF in the ACh-induced relaxation was analyzed.
For this purpose, the vasodilator response to ACh in segments
precontracted high K+ solution (at a concentration that produced
approximately 50–70% of the contraction induced by 120 mM
KCl) was studied. Additionally, the effect of a calcium-activated
potassium channel blockade, produced by apamin (1 mmol/L) plus
TRAM-34 (0.1 mmol/L), on the ACh response was analyzed in
NA-precontracted arteries pretreated or not with tranilast. In
another set of experiments, the effect of L-NAME plus TRAM-34
plus apamin on ACh-induced relaxation was studied. To
determine whether tranilast modified the participation of each
potassium channel individually, concentration response curves to
acetylcholine were performed in the presence of L-NAME plus
apamin or L-NAME plus TRAM-34. All drugs were added
30 min before the concentration-response curve to ACh. Addi-
tionally, to rule out an effect of tranilast on NO mediated
hyperpolarization, concentration-response curves to DEA-NO
were performed in control and tranilast-incubated mesenteric
segments precontracted with a high K+ solution.
The effect of tranilast on the smooth muscle calcium-activated
potassium channels was analyzed. For this purpose, the relaxation
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produced by NS1619 (10 nmol/L-100 mmol/L), a large conduc-
tance calcium-activated potassium channel opener, was analyzed
in NA-precontracted endothelium-denuded arteries preincubated
or not with tranilast.
The participation of COX-derived metabolites was investigated
in tranilast-treated and untreated segments. Arteries were prein-
cubated with the non-specific COX inhibitor indomethacin
(10 mmol/L) before performing concentration-response curves to
ACh.
Nitric Oxide release
Nitric oxide release was determined using the fluorescent probe
4,5-diaminofluorescein (DAF-2), as previously described [19].
Briefly, the second, third and fourth branches of mesenteric artery
were divided in two experimental groups: control and tranilast-
incubated segments (100 mmol/L, 1 hour). After an equilibration
period of 30 min in HEPES (in mmol/L: 119 NaCl, 20 HEPES,
46 KCl, 1 MgSO4.7H2O, 0.15 Na2HPO4.12H2O, 0.4 KH2PO4,
5 NaHCO3, 1.2 CaCl2.2H2O, 5.2 glucose) at 37uC, arteries were
incubated with 2 mmol/L DAF-2 for 45 min and medium was
collected to measure basal NO release. Once the organ bath was
refilled, ACh-induced NO release was measured after an ACh
concentration-curve (0.1 nmol/L - 3 mmol/L) was applied at 2-
min intervals each dose. The fluorescence of the medium was
measured at room temperature using a spectrofluorimeter (LS50
Perkin Elmer Instruments, FL WINLAB Software) with excitation
wavelength set at 492 nm and emission wavelength at 515 nm.
The stimulated NO release was calculated by subtracting the basal
NO release from that evoked by ACh. Also, blank measurement
samples were collected from medium without mesenteric segments
in order to subtract background emission. Some assays were
performed in the presence of L-NAME in order to assure assay
specificity. The amount of NO released was expressed as arbitrary
units/mg tissue.
Detection of superoxide anions
Superoxide anions levels were measured using lucigenin
chemiluminescence, as previously described [20]. Briefly, the
second, third and fourth branches of mesenteric artery, divided in
two experimental groups, control and tranilast-incubated segments
(100 mmol/L, 1 hour), were equilibrated for 30 min in HEPES
buffer at 37uC, transferred to test tubes that contained 1 mL
HEPES buffer (pH 7.4) containing lucigenin (5 mmol/L) and then
kept at 37uC. The luminometer was set to report arbitrary units of
emitted light; repeated measurements were collected during 5 min
at 10 s intervals and averaged. 4,5-dihydroxy-1,3-benzene-dis-
ulphonic acid ‘‘Tiron’’ (10 mmol/L), a cell permeant, non-
enzymatic superoxide anion scavenger, was added to quench the
superoxide anion-dependent chemiluminescence. Also, blank
samples were collected in the same way without mesenteric
segments to subtract background emission.
Drugs
Drugs used were tranilast, atropine, noradrenaline hydrochlo-
ride, acetylcholine chloride, DEA-NO, indomethacin, apamin,
tiron, TRAM-34, NS1619 (Sigma; St. Louis, MO, U.S.A.). Stock
solutions of acetylcholine, apamin, tiron, TRAM-34 and DEA-
NO were made in distilled water, noradrenaline was dissolved in a
NaCl (0.9%)-ascorbic acid (0.01% wv-1) solution; indomethacin
was dissolved in ethanol;tranilast, NS1619 was dissolved in
dimethyl sulfoxide. These solutions were kept at 220uC and
appropriate dilutions were made on the day of the experiment.
Statistical analysis
Contractions to noradrenaline were expressed as the percentage
of contraction of the maximum contractile response induced by a
previous contraction of KCl. Relaxation to ACh, DEA-NO and
NS1619 were expressed as a percentage of the level of
preconstriction induced by noradrenaline or KCl. For each
concentration-response curve the maximum effect (Emax) and
the concentration of agonist that produced half of the Emax (log
EC50) were calculated using non-linear regression analysis
(GraphPad Prism Software, San Diego, CA). The sensitivity of
the agonists is expressed as pD2 (2log EC50).
All values are expressed as means 6 S.E.M. of the number of
animals used in each experiment. Statistical analysis was done by
comparing the curve obtained in the presence of the different
substances with the control curve by means of a non-repeated
measure analysis of variance (ANOVA) followed by the Bonferroni
post-hoc test. Some results were expressed as differences of area
under the curve (dAUC). AUC were calculated from the
individual concentration-response plots. For dAUC, NO and
superoxide anion release experiments, the statistical analysis was
done using one-way ANOVA followed by Newman-Keuls post-
hoc test. P,0.05 was considered significant.
Results
Mast cells were detected in the adventitial layer of mesenteric
arteries using toluidine blue staining (Figure 1).
Preincubation with 100 mmol/L tranilast did not modify
vasoconstrictor response to 120 mmol/L KCl (Control:
14.561.5 mN; Tranilast: 15.161.3 mN/mm; p.0.05), while it
shifted the noradrenaline-induced contractile curve to the right
(Figure 2A). Cumulative addition of ACh evoked endothelium-
dependent relaxations in noradrenaline-contracted arteries.
10 mmol/L and 1 mmol/L tranilast concentrations did not
produce any modification on ACh-induced vasodilation in 1–3
hours incubations (Results not shown), while 1 hour-preincubation
with 100 mmol/L tranilast shifted the concentration response
curve to ACh to the left (Figure 2B and Table 1).
NO synthase inhibitor L-NAME decreased ACh-induced
relaxation to a similar extent in both control and tranilast-
incubated mesenteric segments (Figures 3A and 3B, Table 1).
Relaxation to DEA-NO was not changed by tranilast either in
NA-precontracted or in KCl-precontracted mesenteric arteries
(Figures 3C, Table 2). In line with this, both basal and ACh-
Figure 1. Mast cell localization by toluidine blue staining. Figure
is representative of preparations from four rats. Magnification: 400X
(general vision) and 600X (inset).
doi:10.1371/journal.pone.0100356.g001
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stimulated NO releases were similar in tranilast-treated and
untreated mesenteric resistance arteries (Figure 3D). Preincubation
with L-NAME abolished NO release in all experimental groups
(results not shown). Superoxide anion release was similar in both
tranilast-treated and untreated segments (In chemiluminiscence
units/min mg tissue: Control: 10.9263.5; Tranilast: 12.0363.7;
P,0.05.).
The concentration response curve to ACh was shifted to the
right in KCl-precontracted segments after preincubation with
100 mmol/L tranilast (Figure 4A and 4B). Similarly, preincubation
with apamin plus TRAM-34 shifted the ACh-induced relaxation
leftward to a greater extent in tranilast-incubated segments than in
control segments (Figure 4C and 4D). Combined preincubation
with L-NAME plus TRAM-34 reduced ACh-induced relaxation
similarly in both control and tranilast-incubated segments.
However, preincubation with both L-NAME and apamin shifted
the ACh-induced relaxation to the left more markedly in tranilast-
incubated segments. The remnant vasodilation observed after
preincubation with L-NAME plus TRAM-34 was higher in
tranilast-incubated compared to control segments, while it was
similar in both experimental conditions after preincubation with
L-NAME plus apamin. (Figure 5). Vasodilator response to
NS1619 remained unmodified in presence of tranilast. (Figure 6).
In tranilast-treated and untreated segments, ACh-induced
vasodilation was not modified by indomethacin (Figure 7,
Table 1). In line with this, the combined inhibition of NO and
EDHF through preincubation with L-NAME plus apamin plus
TRAM-34 abolished the increase in relaxation to ACh produced
by tranilast (Figure 7, Table 1).
Discussion
The present results show that tranilast increased the endothe-
lium-dependent relaxation to ACh in rat mesenteric resistance
arteries. This effect is independent of the NO or COX pathways
and seems to be mediated by an increase in EDHF contribution.
Under physiological conditions, mast cells have been identified
in several locations in the mesentery, including around the
mesenteric vessels [14,21]. When activated, mast cells secrete
numerous vasoactive and proinflammatory mediators, such as
histamine, serotonin, bradykinin, endothelin, NO, leukotrienes,
prostaglandins, or cytokines [5], which could alter vascular
endothelial and smooth muscle function [22]. Tranilast is a mast
cell stabilizer used in various pathologies where blood flow is
altered [8–11], such as allergy, which produces an intense
vasodilation produced by histamine release from mast cells. In
this study we have located perivascular mast cells around
mesenteric resistance vessels, as has been described in superior
mesenteric artery [14]. Previously, we have described that tranilast
decreases EFS-induced vasoconstriction in superior mesenteric
arteries [14]. Since total peripheral resistance mainly depends on
Table 1. Effect of indomethacin, L-NAME, Apamin plus TRAM-34 or L-NAME plus Apamin plus TRAM-34 on Emax and pD2 to
acetylcholine in untreated and tranilast-treated MRA.
Untreated Tranilast-treated
Emax pD2 Emax pD2
Control 87.662.03 7.4360.04 93.561.64 8.1260.04+
Indomethacin 85.562.51 7.4460.06 97.165.83 8.1160.13+
L-NAME 71.463.09* 7.2760.07 87.162.18+ 7.6960.11*+
Apamin+TRAM-34 43.565.55* 7.2960.12 46.6.562.82* 7.4760.11*
L-NAME+Apamin+TRAM-34 4.3362.60* - 3.8362.21* -
Values represent means 6 S.E.M.
*P,0.05 vs. situation without specific drugs;
+P,0.05, Tranilast-treated vs. untreated.
doi:10.1371/journal.pone.0100356.t001
Figure 2. Effect of tranilast on endothelial function. NA-induced vasoconstriction in control and tranilast-treated mesenteric resistance arteries
(A).Endothelium-dependent relaxation induced by ACh in NA-precontracted control and tranilast-treated rat resistance arteries (B) Results are
expressed as mean 6 S.E.M. *P,0.05 control vs. tranilast. N = 6–7 animals each group.
doi:10.1371/journal.pone.0100356.g002
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resistance vessels, and the role that mesenteric resistance arteries
play in this is very relevant, we consider it very important to
analyze the possible alterations tranilast may produce in the
endothelial function of these vessels. When analyzing endotheli-
um-dependent relaxation induced by ACh in mesenteric resistance
arteries, we observed an increase in this vasodilator response in
segments preincubated with tranilast. Similar changes in the
endothelial function observed in several pathologic situations in
these vessels are associated to decreased vascular resistance and
subsequent hemodynamic changes [19,23]. This outcome con-
trasts with previous studies, in which ACh-induced vasodilation
was not modified by tranilast in superior mesenteric artery or
aorta, despite the longer treatment period used [14,15]. These
results indicate that tranilast can modify endothelial factor release
and/or sensitivity differentially depending on the vascular bed
analyzed, which is not surprising since we have previously
described a similar effect in these vascular beds [24], probably
associated to differences in the composition of endothelial factors.
Previous studies show that endothelial dysfunction is related to
an increase in the vasoconstrictor responses to different agonists
and vice versa [20,25,26]. In our experimental conditions,
vasoconstriction produced by KCl remained unmodified in the
presence of tranilast, similar to observations in superior mesenteric
arteries [14], suggesting that this drug does not modify vascular
contractile capacity. Additionally, when analyzing the vasocon-
strictor response to the alpha-adrenergic agonist noradrenaline, we
observed that response was decreased in tranilast-incubated
segments, similarly to descriptions in superior mesenteric artery
[14], but in contrast to observations in rat aorta [15].
The relaxation evoked by ACh is mediated, depending on the
vascular bed analyzed, by the release of endothelium-dependent
relaxing factors such as NO, prostacyclin, and EDHF [27–29]. In
Table 2. Emax and pD2 values of DEA-NO in untreated and tranilast-treated MRA.
Untreated Tranilast-treated
Emax pD2 Emax pD2
NA-precontracted 96.9565.12 5.7860.13 94.2564.46 5.7360.10
KCl-precontracted 70.8963.31* 5.8760.23 72.9764.07* 5.6160.12
Values represent means 6 S.E.M.
*P,0.05 KCl precontraction vs. NA precontraction.
*P,0.05 NA-precontracted vs. KCl precontracted.
doi:10.1371/journal.pone.0100356.t002
Figure 3. Participation of NO on the vasodilator response to acetylcholine. Effect of L-NAME (100 mM) on the concentration-dependent
relaxation to ACh in control (A) and tranilast-treated (B) mesenteric resistance arteries. Insert graph shows the differences of area under the curve
(dAUC) in control and tranilast-treated arteries pre-treated with L-NAME. Results are expressed as mean 6 SEM. N= 6–7 animals in each group. (C)
Vasodilator response to DEA-NO in control and tranilast-incubated mesenteric resistance arteries, precontracted with either noradrenaline or KCl.
Results are expressed as mean 6 S.E.M. N = 5–6 animals each group. (D) Effect of tranilast on basal and acetylcholine-induced NO release in rat
mesenteric resistance arteries. Results (mean 6 S.E.M.) are expressed as arbitrary fluorescence units (A.U.)/mg tissue. N = 4 animals each group. *P,
0.05 vs. basal.
doi:10.1371/journal.pone.0100356.g003
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Figure 4. Participation of EDHF in the vasodilator response to acetylcholine. Relaxation to acetylcholine in control (A) and tranilast-treated
arteries (B) pre-contracted with KCl. Effect of preincubation with 1 mM apamin plus 0.1 mM TRAM-34 on endothelium-dependent relaxation to
acetylcholine in noradrenaline-pre-contracted control (C) and tranilast-treated arteries (D). Insert graph shows the differences of area under the curve
(dAUC) in control and tranilast-treated arteries either preconstricted with KCl or pre-treated with TRAM-34 plus Apamin. Results are expressed as
mean 6 SEM. *P,0.05 control vs. tranilast. N = 5–7 animals in each group.
doi:10.1371/journal.pone.0100356.g004
Figure 5. Participation of potassium channels in the vasodilator response to acetylcholine. Effect of preincubation with 100 mmol/L L-
NAME plus 1 mM apamin or plus 0.1 mM TRAM-34 on endothelium-dependent relaxation to acetylcholine in noradrenaline-pre-contracted control (A)
and tranilast-treated arteries (B). Results are expressed as mean 6 SEM. *P,0.05 control vs. tranilast N = 5–7 animals in each group. (C) Differences of
area under curve (dAUC) in the absence or presence of 100 mmol/L L-NAME plus 1 mM apamin or plus 0.1 mM TRAM-34. Results are expressed as
mean 6 SEM. dAUC values are expressed as percentage. *P,0.05 control vs. tranilast. N = 5–7 animals each group. (D) Representation of remnant
acetylcholine-induced vasodilation after preincubation with 100 mmol/L L-NAME plus 1 mmol/L apamin or plus 0.1 mM TRAM-34, expressed as mean
6 SEM of percentage of AUC. *P,0.05 control vs. tranilast. N = 5–7 animals each group.
doi:10.1371/journal.pone.0100356.g005
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rat mesenteric resistance arteries this relaxation is mainly mediated
by the release of NO and EDHF [30], but not by COX-derived
products [31]. Contradictory effects of tranilast on NO release
have been described, since both increases [32], decreases
[14,33,34] and no modifications [15] of NO release have been
reported in several tissues after tranilast preincubation. Addition-
ally, multiple studies have described an antioxidant effect of
tranilast treatment in both in vivo and in vitro experimental
procedures [14,32,33,35–39]. With this in mind, the effects
produced by tranilast in ACh-induced vasodilation could be
mediated by changes in NO synthesis and/or bioavailability. In
order to analyze this possibility, we preincubated control and
tranilast-exposed mesenteric resistance segments with the non-
specific NOS inhibitor L-NAME. We observed that, after
preincubation with this drug, ACh-induced relaxation was
decreased to a similar extent in both experimental conditions
indicating that NO does not participate in the effect observed after
preincubation with tranilast. This was confirmed by the fact that
NO release, superoxide anion formation and vasodilator response
to NO donor DEA-NO were not modified after preincubation
with tranilast, similarly to reported in rat aorta [15]. All these
results contrast with our previous results in superior mesenteric
artery, where we observed decreases in neuronal NO and
superoxide anion releases and an increase in the vasodilator
response to DEA-NO after tranilast preincubation [14]. In
conclusion, the results obtained in the present study confirm the
fact that the increased vasodilator response to ACh produced by
tranilast is not due to modifications in the NO pathway.
Hyperpolarizing mechanisms are important regulators of the
membrane potential and hence of vessel tone [29], this mechanism
being particularly important in small arteries and arterioles.
Although controversial, NO has been described to exert a
hyperpolarizing role in several vascular beds [40,41]. This
hyperpolarization produced by NO can be due to an activation
of different potassium channels, including large-conductance
calcium dependent potassium channels and voltage-dependent
potassium channels [42]. Thus, the effects of tranilast on non-
membrane potential-dependent actions of DEA-NO were inves-
tigated in arteries preconstricted with a high K+ solution, thus
blocking hyperpolarization by decreasing the plasma membrane
potassium gradient [43]. The results showed that, in KCl-
precontracted arteries, the vasodilator response induced by
DEA-NO was reduced to a similar extent in control and
tranilast-incubated mesenteric segments, confirming the hyperpo-
larizing role of NO in this vascular bed, and also that this effect is
not altered by tranilast.
EDHF plays, in addition to NO, an important vasodilator role
in resistance vessels. The relaxation induced by EDHF is
endothelium-dependent, insensitive to inhibition by a combination
of NOS and COX inhibitors, and leads to hyperpolarization of
vascular smooth muscle cells [44]. In order to determine whether
the increase in ACh-induced vasodilation induced by tranilast is
due to an increase in EDHF participation, control and tranilast-
incubated mesenteric resistance arteries were precontracted with a
high K+ solution. We observed that, in this experimental
condition, vasodilation to ACh was reduced in both control and
tranilast-incubated segments, but more markedly in segments
exposed to tranilast. Initially, the EDHF-mediated response was
attributed to activation of small, intermediate and large conduc-
tance calcium-activated K+-channels, although the participation of
the latter has been questioned [45–49]. In presence of a
combination of small (SKCa) and intermediate conductance
calcium-activated K+-channel (IKCa) blockers (apamin+TRAM-
34, respectively), we also observed a greater inhibition of the ACh-
induced vasodilation in tranilast-preincubated segments compared
to control segments. However, a differential effect of tranilast on
each type of calcium-activated potassium channel must also be
considered. The fact that a combined preincubation with L-
NAME plus TRAM-34 decreased ACh-induced relaxation
Figure 6. Vasodilator response to K+-channel openers. Effect of
tranilast on the relaxation to the large conductance calcium-activated
K+-channel opener NS1619 in de-endothelized rat mesenteric arteries.
Results are expressed as mean 6 SEM. N= 5–7 animals in each group.
doi:10.1371/journal.pone.0100356.g006
Figure 7. Participation of prostanoids in the vasodilator response to acetylcholine. Effect of preincubation with 10 mM indomethacin or
with 100 mmol/L L-NAME plus 1 mM apamin plus 0.1 mM TRAM-34 on the concentration-dependent relaxation to ACh in control (A) and tranilast-
treated (B) rat mesenteric resistance arteries. Results are expressed as mean 6 S.E.M. *P,0.05 control vs. tranilast. N = 6–7 animals in each group.
doi:10.1371/journal.pone.0100356.g007
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similarly in both experimental conditions, while a combination of
L-NAME plus apamin produced a more marked decrease in ACh-
induced relaxation in tranilast-incubated segments, suggests a
greater participation of SKCa channels through tranilast prein-
cubation. These findings indicate that hyperpolarization produced
by EDHF is responsible for the tranilast-mediated effects on the
ACh-induced dilation in mesenteric resistance arteries, due to an
increased SKCa channel participation after preincubation with
tranilast. Since the importance of the hyperpolarizing mechanism
in endothelium-dependent relaxations increases as the vessel size
decreases [50,51], this result can explain the difference in the effect
of tranilast on ACh-induced vasodilation previously observed in
superior mesenteric artery and aorta, where the role of EDHF in
endothelium-dependent relaxation is essentially absent [14,15].
The greater participation of EDHF in ACh-induced response in
tranilast-incubated arteries may be associated to an increase in
potassium channel activation by EDHF or to an increase in EDHF
generation. The fact that the vasodilation induced by NS1619 (a
large conductance calcium-activated K+-channel opener) was not
altered in the presence of tranilast seems to rule out a greater
activation of these channels by the tranilast effect. However, we
must take into account that these channels are also present in
endothelial cells, whose activation alters the release of several
vasoactive substances [52–56]. Taken together our results indicate
that tranilast increases the vasodilator response to ACh through a
mechanism that implicates a greater participation of EDHF. This
effect seems to be associated with a greater activation of SKCa
channels, without modifying the participation of IKCa channels,
As we have previously reported [31], COX-derived products do
not participate in the relaxation induced by ACh in control
situations in mesenteric resistance arteries. However, in some
pathological situations, such as hyperaldosteronism, we have also
described participation by COX-derived products in vascular
function, including relaxation to ACh [19,31]. In the present
study, the COX inhibitor indomethacin did not affect the
relaxation to ACh in the absence or presence of tranilast,
confirming the non-participation of COX-derived products in
both experimental conditions. The fact that in the presence of L-
NAME plus TRAM-34 plus apamin the relaxation to ACh was
abolished confirmed this observation, since it demonstrates that
the vasodilator response to ACh is only due to NO and EDHF in
these experimental conditions.
In summary, tranilast increased the endothelium-dependent
relaxation to acetylcholine in rat mesenteric resistance arteries.
This effect is independent of the NO and COX pathways but
involves EDHF, and is mediated by an increased role of small
conductance calcium-activated K+ channels. Similar alterations in
endothelial function in this vascular bed have been associated to
altered splanchnic circulation and the development of organ
failure [19]. Therefore, these results lead us to consider it
important to evaluate the hemodynamic conditions of patients
receiving treatment with tranilast.
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